Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 1/20 | 0.49 |
| ▸ | FPR2 | P25090 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 5/20 | 0.48 |
| ▸ | TDO2 | P48775 | 5/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | PRKCI | P41743 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468927 | 0.83 | LTA4H (0.44) | IDO1TDO2LTA4HHTR6PRKCI | |
| SCHEMBL10839151 | 0.83 | LTA4H (0.44) | IDO1TDO2LTA4HHTR6PRKCI | |
| SCHEMBL1116569 | 0.83 | LTA4H (0.52) | LTA4HHTR6IRAK4 | |
| SCHEMBL3329262 | 0.83 | LTA4H (0.52) | LTA4HHTR6IRAK4 | |
| SCHEMBL1116568 | 0.83 | LTA4H (0.52) | LTA4HHTR6IRAK4 | |
| SCHEMBL14416942 | 0.81 | PRKCI (0.51) | IDO1TDO2LTA4HPRKCI | |
| SCHEMBL14409567 | 0.81 | PRKCI (0.51) | IDO1TDO2LTA4HPRKCI | |
| SCHEMBL14416943 | 0.81 | PRKCI (0.51) | IDO1TDO2LTA4HPRKCI | |
| SCHEMBL4654443 | 0.81 | LTA4H (0.51) | LTA4HHTR6IRAK4 | |
| SCHEMBL1751545 | 0.81 | LTA4H (0.51) | LTA4HHTR6IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592358-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| EP-1737823-A2 | NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005103002-A2 | NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | disclosed |
| US-20050234101-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234101-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | FPR3 408/4885FPR2 584/4885IDO1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.